Chinese Fibromyalgia Market : Opportunities, Demand and Forecasts, 2020–2027

 Fibromyalgia syndrome is a condition characterized by widespread musculoskeletal pain. Patients with fibromyalgia may also have muscle stiffness, increased sensitivity to pain, problems with mental processes, fatigue, irritable bowel syndrome (IBS), and others. As symptoms of fibromyalgia syndrome mimic other chronic diseases, therefore its diagnosis takes a long time. According to a study published in Arthritis Research & Therapy journal in 2017, in Taiwan, the risk of coronary heart disease in fibromyalgia patients was 47% higher than in the general population. For fibromyalgia to be diagnosed, the differential diagnosis is most commonly used.  Other diagnostic procedures, such as laboratory evaluations are also used.

Notably, increasing cases of rheumatic diseases and growing geriatric population are the key factors driving the Chinese fibromyalgia market. According to the study published in Aging Clinical and Experimental Research in 2014, fibromyalgia syndrome can affect people of all age group, with the high prevalence in the elderly population as the geriatric population is more vulnerable towards pain, reduced mobility, and sleep disruption. In the general population, the prevalence of fibromyalgia increases by 2% at the age of 20 to 8% at the age of 70.

Browse Sample of the Report @  https://www.marketresearchfuture.com/sample_request/5630

Growing awareness among the population, and rising incidences of traumatic stress and road accidents are also fueling the market growth. According to a study published in Pain Research and Management journal, in 2014, it was found that physical trauma is followed by fibromyalgia syndrome. In this study, conducted with a specific cohort of individuals involved in a motor vehicle collision, found that 8% of individuals developed widespread chronic pain. Widespread chronic pain characterizes fibromyalgia.

However, difficulty in diagnosis may hinder the growth of the market over the forecast period. Fibromyalgia can’t be easily confirmed as the condition is commonly expressed with many other accompanying chronic disorders such as rheumatic diseases, neurological disorders, mental health problems, and others

Chinese fibromyalgia market is expected to grow at a CAGR of 18.7% during the forecast period 2017-2022.

Intended Audience

• Pharmaceutical Companies
• Hospitals & Clinics
• Research and Development (R&D) Companies
• Government Research Institute
• Academic Institutes and Universities

Segmentation

The Chinese fibromyalgia market is segmented on the basis of diagnosis, treatment, and end-user.

On the basis of the diagnosis, the market is classified into laboratory evaluation and presence of central sensitization.

On the basis of the treatment, the market is segmented into targeted treatment and symptomatic treatment.

On the basis of the end-users, the market is segmented into hospitals, clinics, diagnostic centers, and others.

Key Findings

• The Chinese fibromyalgia market is expected to reach USD 3,079.1 million by 2022 at a CAGR of 18.7%
• On the basis of the diagnosis, the laboratory evaluation segment is expected to command the largest market share of 77.2% over the review period, and it is also expected to grow at the fastest CAGR of 19.1% during the forecast period 2017-2022
• On the basis of the treatment, the symptomatic treatment segment is expected to command the largest market share of 68.6% over the review period, and targeted treatment is expected to grow at the fastest CAGR of 19.2% during the forecast period 2017-2022
• South Central China holds the largest share of the Chinese fibromyalgia market and is expected to reach USD 785.3 million by 2022
• North China is the fastest growing market, which is expected to grow at a CAGR of 19.2% over the forecast period 2017-2022

Regional Analysis

South Central China accounted for the major share of the market owing to the rising prevalence of fibromyalgia in this region. Rising cases of chronic rheumatic diseases are also capable of fuelling the fibromyalgia market in China. Prevalence of rheumatoid arthritis is around 0.35%, with the significantly higher rate in Northern China as compared to the Southern part.

The rising healthcare expenditure is also propelling the growth of the market. In China, the total expenditure on health per capita in 2014 was USD 731, as per the World Health Organization (WHO) in 2015. The health expenditure in China grew at a rate of 11.6% per year, suggested by a study published in BMC Health Services Research journal in 2017. This rate is much faster than the growth of the country’s economy, i.e. 9.9% per year.

Key Players

Some of key the players in the market are Pfizer, GlaxoSmithKline, AstraZeneca, Roche, Astellas Pharma, Eli Lilly and Company, Johnson & Johnson Services, Inc., SANOFI, Bayer AG, AbbVie, ALLERGAN, Boehringer Ingelheim, Cephalon, Inc., Vertical Pharmaceuticals, Sunovion Pharms Inc, Jazz Pharmaceuticals, ABBOTT, NOVARTIS, and others.

Browse More Details of the Report @ https://www.marketresearchfuture.com/reports/chinese-fibromyalgia-market-5630

Trends in the Sentinel Node Biopsy Market 2020-2027

 A sentinel lymph node biopsy is a medical procedure, which involves identification, removal, and examination of the lymph node to verify the presence of cancer cells. Lymph nodes are a part of the lymphatic system which is found throughout the body and is connected to the lymph vessels.  Breast cancer, melanoma, colon cancer, esophageal cancer, head and neck cancer, non-small cell lung cancer, stomach cancer, thyroid cancer are various indications for biopsy. The procedure helps the healthcare provider to determine the stage of cancer, its metastasis in order to plan a line of treatment for the patient.

Browse Sample of the Report  @ https://www.marketresearchfuture.com/sample_request/5582

Rising prevalence of various types of cancer such as breast cancer, melanoma, colon cancer and growing emphasis on women healthcare are the major drivers for the growth of the market. Additionally, increasing number of health problems women further fuel the market growth. Demand for diagnosis and treatment of breast cancer and the technologically advanced medical device is found to be increasing across the globe.  Furthermore, increasing healthcare expenditure and overall growth of healthcare industry also influence the market growth. Extensive research in the field of reproductive health and diseases also boost the market. Increasing demand for new products and accessories with advent of technology in the healthcare industry also fuels the growth of the market across the globe. However, various factors restrained the market growth such as complications associated with the biopsy and unawareness among women.

The global sentinel node biopsy market is expected to grow at a CAGR of 5.1% during the forecast period.

Segments                                                                                                                                            

The global sentinel node biopsy market is segmented on the basic product, indication, and end user.

On the basis of product, market is segmented into breast localization wire, tissue marker, gamma probe, drainage catheter, and others

On the basis of indication, the market is segmented into breast cancer, melanoma, colon cancer, esophageal cancer, and others.

On the basis of the end user, the market is segmented into hospitals & clinics, diagnostic centers, and others.

Intended Audience

• Medical Device Manufacturers
• Medical Device Suppliers
• Medical Research Laboratories
• Healthcare IT Companies
• Research and Development (R&D) Companies
• Market Research and Consulting Service Providers
• Potential Investors

Regional Analysis of the Global Sentinel node biopsy Market             

America captures the first position in the market for sentinel node biopsy whose market is driven by increasing number of women suffering from breast disorders and rising prevalence of breast cancer in the U.S. and Canada. Furthermore, the market is also driven by the availability of technologically advanced medical devices and quality care in healthcare institutes. In Americas, North America is the major market due to increasing number of market players offering biopsy devices and instruments. As per the American Cancer Society, in 2015, there were 231,840 new cases of breast cancer, and till March 2017, there were 3.1 million women with a history of breast cancer in the U.S. As per the National Cancer Institute, 2016, in the U.S. around 1,685,210 new cases of cancer were diagnosed and in 2014, around 15,780 children and adolescents ages 0 to 19 were diagnosed with cancer and 1,960 died of the disease.

In Europe, sentinel node biopsy market shows better growth opportunities governed by the ongoing research and development activities in the field of oncology. In Europe, there is an increasing demand for medical devices and availability of funds for research and development activities in the reproductive health. Germany acquires the first position the European market owing to an increasing demand for cancer diagnosis. France and U.K secure second and third position are respectively owing to the availability of tertiary care facilities in these countries and rising healthcare expenditure.

The Asia Pacific is the fastest growing region in the market whose growth is determined by the presence of highly skilled workforce and increasing demand for biopsy procedures in hospitals and specialty care centers. India and China exhibit enormous growth opportunities owing to ever increasing the prevalence of chronic diseases, increase in a number of women suffering for reproductive disorders, and increasing expenditure on surgical procedures industry by key players in developing economies throughout the Asia Pacific.

In the Middle East, Saudi Arabia and the United Arab Emirates are the major countries holding the largest share in the market. Increase in the number of specialty care services and rising demand for diagnosis of various types of cancer are the key drivers of the market. Africa exhibits slow growth owing to limited penetration of technology in this region and unawareness about sentinel node biopsy.

Browse More Details of the Report @

 https://www.marketresearchfuture.com/reports/sentinel-node-biopsy-market-5582

Key Players in the Global Sentinel Node Biopsy Market          

Some of the key players in this market are Devicor Medical Products, Inc., part of Leica Biosystems. (Germany), C. R. Bard, Inc. (U.S.), INTRAMEDICAL IMAGING LLC (U.S.), Hilfe Engineering Corporation (India), Surgic Eye (Germany), KUB Technologies, Inc. (U.S.), Navidea Biopharmaceuticals, Inc.(U.S.) and others.

Trends in the Hematocrit Test Market 2020-2027

 Also known as packed-cell volume (PCV) test, hematocrit test is used to measure the percentage of Red Blood Cells (RBCs) in the blood. The major function of the RBCs is to carry blood throughout the body. The test is usually performed to diagnose various diseases such as anemia, leukemia, lymphoma, congenital heart disease, and others. The test determines the elevation in the percentage of normal RBCs which is 38.8%-50% in men and 34.9%-44.5% in women. The hematocrit test is one of the tests included under complete blood count (CBC) test.

Browse Sample of the Report @  https://www.marketresearchfuture.com/sample_request/5553

Cardiovascular diseases, cancer, and kidney diseases are increasing the economic burden of various developing and developed nations across the globe. The market for hematocrit test is driven by rising prevalence of chronic diseases such as cardiovascular diseases, diabetes, and others along with changing lifestyle, and increasing demand for diagnostic devices for cardiovascular diseases. However, limited number of trained personnel has restrained the growth of the market. However, the high cost of diagnosis and treatment of cardiovascular diseases also restrains the growth of the market. As per the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), the overall prevalence of Chronic Kidney Disease (CKD) in the general population across the globe is nearly 14%. However, the growth of the market is restrained by the inaccurate or misleading result of the test and unawareness about hematocrit test in the diagnosis of the disease.

The global hematocrit test market is expected to grow at a CAGR of 4.5% during the forecast period.

Segments                                                                                                                                          

The global hematocrit test market is segmented on the basis of product, indication, devices, and end-user.

On the basis of product, the market is segmented into the analyzer, hematocrit test meter, and others.

On the basis of indication, the market is segmented into anemia, leukemia, lymphoma, congenital heart disease, kidney tumor, and others.

On the basis of the end-user, the market is segmented into hospitals & clinics, diagnostic centers, and others.

Intended Audience

• Medical Device Manufacturers
• Medical Device Suppliers
• Medical Research Laboratories
• Research and Development (R&D) Companies
• Market Research and Consulting Service Providers
• Potential Investors

Regional Analysis of the Global Hematocrit Test Market                      

The global hematocrit test market consists of four major regions namely, the Americas, Europe, Asia Pacific and the Middle East & Africa, with the Americas capturing the largest market share. The growth of the market is attributed to an increase in the demand for diagnostic procedures, and rising importance of hematology testing for the diagnosis of various chronic diseases. North America accounts for the major share in the American hematocrit test market which is attributed to extensive use of hematocrit test with other diagnostic tests. According to the Center for the Disease Control and Prevention (CDC), as of 2012, nearly half of all the adults, 117 million population in the U.S. had one or more chronic health conditions. One in four adults were diagnosed with two or more chronic health diseases.

In Europe, the growth of the market is driven by increasing demand for diagnostic devices and instrument in hospitals and diagnostic centers. Germany, the U.K, and France are the major contributors to the growth of the market owing to an increase in the number of key players engaged in the manufacturing of medical devices and instruments and rising expenditure in research and development by these major economies. Additionally, well-developed healthcare sector, ever-increasing patient population and high healthcare expenditure by the European nations fuel the market growth.

The Asia Pacific is expecting the fastest growth in the market due to the flourishing growth of healthcare industries in developing economies such as India. Additionally, the ever-increasing prevalence of kidney diseases and cardiovascular diseases and rising demand for quality devices in the healthcare sector is expected to lead the use of advanced equipment, which, in turn, may speed up the market growth in the region. Rising geriatric population with chronic diseases further creates the economic burden on the developing nations thereby accelerating the market growth.

The Middle East & Africa hold the least share in the market. The market in this regions exhibits steady growth owing to an increase in the demand for the diagnostic and treatment services.  In the Middle East and Africa, the United Arab Emirates (UAE) hold the largest market share owing to the availability of diagnostic and treatment services. Africa shows slow growth due to low technology penetration in developing countries.

Key Players in the Global Hematocrit Test Market         

Some of the key players in this market are Abbott (U.S.), F. Hoffmann-La Roche Ltd (Switzerland), Siemens AG (Germany), Beckman Coulter, Inc. (U.S.), Bio-Rad Laboratories, Inc. (U.S.), Horiba, Ltd. (Japan), Mindray Medical International Limited (China), Boule Diagnostics AB (Sweden), Nihon Kohden Corporation (Japan), Sysmex Corporation (Japan), and others.

Browse More Details of the Report @ https://www.marketresearchfuture.com/reports/hematocrit-test-market-5553

Dravet syndrome Market Detailed Industry Report Analysis 2020-2027

 Dravet syndrome is a rare genetic epileptic encephalopathy that begins during the first year of life in an otherwise healthy infant. According to the National Center for Advancing Translational Sciences, in 15% to 25% cases of the Dravet syndrome, a family history of epilepsy or febrile seizures exists. It is also reported that 85% cases of Dravet syndrome originated due to a mutation in the SCN1A gene.

It is noted that development of new drugs and therapies, and rising R&D expenditure are propelling the growth of the market. In recent years, Dravet syndrome has gained significant attention due to the upcoming drugs for its treatment. For instance, on February 06, 2018, Zogenix, Inc. received breakthrough therapy designation from FDA for its product, ZX008. The drug is specialized for the treatment of Dravet syndrome and its related complications.

Browse Sample Copy of the Report @ https://www.marketresearchfuture.com/sample_request/5509

Various other factors such as unmet medical needs, increasing government assistance, rising healthcare expenditure in the developed countries, improving regulatory framework, increasing adoption rate, and rising funding and reimbursement policies are continuously contributing to the growth of the global Dravet syndrome market.

Despite these drivers, there are some issues associated with Dravet syndrome market. The side effects of drugs and other therapeutic agents, lack of awareness in the developing countries, and poor healthcare system in low and middle-income countries, may hinder the growth of the market.

It is estimated that the Dravet syndrome market is expected to grow at a CAGR of 8.5% during the forecast period of 2017-2023.

Intended Audience:

• Pharmaceutical Companies
• Research and Development (R&D) Companies
• Government Research Institute
• Academic Institutes and Universities

Key Players:

Some of key the players in the global dravet syndrome market are Biocodex, Biscayne Neurotherapeutics, Cyberonics, Inc., Epygenix Therapeutics, Inc., GW Pharmaceuticals, plc, INSYS THERAPEUTICS, INC., OPKO Health Inc., Ovid Therapeutics, PTC Therapeutics, Sage Therapeutics, Takeda Pharmaceutical Company Limited, Thermo Fisher Life Technologies, Xenon Pharmaceuticals, Zogenix, Inc, and others.

Segmentation:

The global Dravet syndrome market is segmented on the basis of the type of seizures, diagnosis, treatment & management, and end-user.

On the basis of the type of seizures, the market is classified as myoclonic seizures, atonic seizures, partial seizures, absence seizures, tonic clonic seizures, photosensitive seizures, and others.

On the basis of the diagnosis, the market is classified as magnetic resonance imaging (MRI), electroencephalography (EEG), SCN1A testing, and others.

On the basis of the treatment & management, the market is classified as seizure medications, ketogenic diet, vagus nerve stimulation (VNS), and others. The seizure medications segment is further classified into clobazam, stiripentol, sodium valproate, and others.

On the basis of the end-user, the market is segmented into pharmaceutical companies, hospitals, diagnostic laboratories, academic and research institutes, and others.

Browse More Details of the Report @ https://www.marketresearchfuture.com/reports/dravet-syndrome-market-5509

Parathyroid Disorders Market : Opportunities, Demand and Forecasts, 2020–2027

 Parathyroid glands produce and secrete a parathyroid hormone which is involved in regulation of calcium and phosphorus metabolism. Hyperparathyroidism and Hypoparathyroidism are the two most common parathyroid disorders. The hyperparathyroidism is characterized by an excessive secretion of parathyroid hormone. The most common signs and symptoms of the disorder include kidney stones, bone and joint pain, fragile bones, weakness.

According to a study published in the Turkish Journal of Trauma and Emergency Surgery in 2016, it is found that hyperparathyroidism is the third most common clinical endocrine disorder with a prevalence between 0.1–1.0%, and an incidence of around 28 cases per 100,000 individuals. It also reported that the incidence rate is highest between 50 and above age group i.e. the condition is affecting 2% of the population aged 55 years or older.

Browse Sample of the Report @  https://www.marketresearchfuture.com/sample_request/5451

Notably, rising prevalence of parathyroid disorders and growing geriatric population are the key factors driving the parathyroid disorders market.

Various other factors such as increasing incidences of parathyroid disorders, increasing government assistance, rising healthcare expenditures, improving regulatory framework, and rising funding and reimbursement policies are continuously contributing to the growth of the global parathyroid disorders market. According to the data suggested by Eurostat, it is observed that among the EU Member States, the highest value of healthcare expenditure was recorded in Germany in 2014 i.e. EUR 321 billion, which is further followed by France with EUR 237 billion, and the United Kingdom with EUR 223 billion.

Despite these drivers, there are some issues associated with parathyroid disorders market. Some of the challenges include less research and development funding, side-effects of treatment, the presence of misbranded and spurious drugs, expiration of patented drugs and poor healthcare system in low and middle-income countries may hinder the growth of the market to an extent.

It is estimated that the parathyroid disorders market is expected to grow at a CAGR 6.5% during the forecast period of 2017-2023.

Intended Audience:

• Pharmaceutical Companies
• Research and Development (R&D) Companies
• Medical Device Companies
• Diagnostic Laboratories
• Government Research Institute
• Academic Institutes and Universities

Segmentation

The global parathyroid disorders market is segmented on the basis of type, diagnosis, treatment, and end-user.

On the basis of the type, the market is classified as hyperparathyroidism (HPT), parathyroid cancer, and hypoparathyroidism. The hyperparathyroidism is further segmented into primary hyperparathyroidism, secondary hyperparathyroidism, and tertiary hyperparathyroidism.

On the basis of the diagnosis, the market is classified as blood tests, imaging tests, and urine tests. The imaging tests is further sub-segmented into CT or CAT (computed axial tomography) scans, MRI (magnetic resonance imaging) scans, X-ray, ultrasound, bone density test, and sestamibi scan.

On the basis of the treatment, the market is classified as surgery, radiation therapy, drugs, and others. The drugs segment is further sub-segmented into calcimimetics, hormone replacement therapy, and bisphosphonates.

On the basis of the end-user, the market is segmented into hospitals & clinics, diagnostic centers, drug stores, pharmacies, and others.

Regional Analysis:

The Americas dominate the global parathyroid disorders market owing to the rising prevalence of parathyroid disorders and high healthcare expenditure. According to the Centers for Disease Control and Prevention in 2015, the total health expenditure in the United States was reported to be USD 3.2 trillion and hospital care accounted for a share of 32.3%.

Europe holds the second position in the parathyroid disorders market. It is expected that the support provided by the government bodies for research & development and improvement in the reimbursement policies in the healthcare is likely to drive the market of the European region.

The Asia Pacific region is the fastest growing parathyroid disorders market owing to a huge patient pool and developing healthcare technology. Healthcare expenditure is also improving in various Asia Pacific countries. According to the Australian Institute of Health and Welfare in the years 2015-2016, the total health expenditure was USD 170.4 billion, which is 3.6% higher than the expenditure of 2014-2015.

The Middle East & Africa holds the least market share due to lack of technical knowledge and poor medical facilities.

Key Players

Some of the key players in the global parathyroid disorders market are Abbott Laboratories, Alcon Laboratories, Inc., Amgen Inc., Bayer Healthcare, Becton, Dickinson and Company, Eli Lilly, Ethicon, Inc., Genentech, Medtronic, Merck, Mylan Laboratories, Novartis, Novo Nordisk, Pfizer, Roche, Smith & Nephew plc, Stryker, Teva Pharmaceutical Industries Ltd., Zimmer Biomet Holdings, Inc., and others.

Browse More Details of the Report @ https://www.marketresearchfuture.com/reports/parathyroid-disorders-market-5451

Sterility Testing Market Growth, Demands, CAGR, Sales Volume, Opportunities, Types, Applications and Forecast up to 2027

  The global sterility testing market is anticipated to reach USD 1,245.2 million by 2023, as per a new detailed report by Market Research Future (MRFR). It is expected to exhibit an 11.7% CAGR during the assessment period (2017-2023). High prevalence of cardiovascular diseases and various cancers are expected to induce market demand. Government support in terms of funding coupled with the expanding life science sector is anticipated to bode well for the market during the forecast period.

Sterility testing is essential for research and development purposes in pharmaceutical companies. It is a crucial step for determining the safety of drugs before consumption. In addition, sterility testing is also conducted in specific rooms in facilities to keep it germ-resistant. Drugs and vaccines undergone sterility testing can be commoditized and made commercially available to the masses. This can be beneficial to patients afflicted with cancer and cardiovascular diseases.

Browse Sample of the Report @ https://www.marketresearchfuture.com/sample_request/547

Report Overview

This report allows the user to gain a deeper understanding of the ongoing events and trends in the global market for sterility testing. By correlating the historical data with key market dynamics, analysts were able to make highly accurate projections in the report. MRFR’s report includes a thorough segmental analysis of the global sterility testing market segmented by product type, test type, end-user, and region with astute insights. This report has been prepared to assist industry participants in making informed decisions on growth strategies and operation management. Users will also come across drivers, trends, opportunities, and restraints which are likely to influence the growth of the market during the assessment period.

Segment Overview

By product type, the sterility testing market has been segmented into instruments, consumables, and services. The services segment is further segmented into sterility assurance tests, sterility validations, cleaning and disinfection, and stability testing. By test type, the market is segmented into product flush sterility testing, membrane filtration sterility testing, direct transfer sterility testing, and others. By end-user, the market is segmented into academic and research laboratories, pharmaceutical companies, hospitals and clinics, and others.  

The segments and sub-segments covered in the report are analyzed under four major regions –Americas, Europe, Asia Pacific (APAC), and the Middle East and Africa (MEA), with respective country-level market sizing. For the scope of research, the standard definition of the product/ service “sterility testing” is included in the report. The report discusses and interprets the current and future opportunities of the industry delivering an unbiased growth assessment.

Players Covered

Bioquell U.K. Ltd., Belimed Deutschland GmbH, Baxter BioPharma Solutions, Charles River Laboratories Inc., Boston Scientific Corporation, BioMérieux SA, Thermo Fisher Scientific Inc., SGS SA, Pacific BioLabs Inc., WuXi AppTec, Astell Scientific, Sartorius AG, Becton, Dickinson and Company, Merck KGaA, and others are prominent players in the sterility testing market.

The report offers comprehensive profiles on these market players and assesses their current standing in the sterility testing market. Company history coupled with annual turnover, segmental share, SWOT analysis, growth strategies, new product launches, M&A activities, and latest R&D initiatives are outlined in the report.

Research Methodology

Market Research Future (MRFR) uses a combination of primary and secondary research to compile market reports. Primary data is accumulated from interviewing industry stalwarts and secondary research is collated by studying white papers and annual reports of leading players. Our analysts use top-down and bottom-up approaches to validate the findings of the report. The report consists of news, current trends, and future prospects related to the market, all of which can provide a thorough understanding of the market to clients. Industry leaders can make accurate business decisions based on our insights.

Browse More Details of the Report @ https://www.marketresearchfuture.com/reports/sterility-testing-market-547

Ischemic stroke Market Growth, Demands, CAGR, Sales Volume, Opportunities, Types, Applications and Forecast up to 2027

  Ischemic strokes occur as a result of an obstruction within a blood vessel supplying blood to the brain. The underlying condition of this type of obstruction is the development of fat deposits lining the vessel walls, which is known as atherosclerosis. According to the World Health Organization (WHO), stroke accounts for around 17 million deaths annually. As per the Centers for Disease Control and Prevention (CDC), stroke leads to 1 out of every 20 deaths costing around USD 34 billion each year in the U.S. Higher rates of mortality associated with strokes highlight an impending need for innovative drugs and diagnostic devices.

The key strategies adopted by leading industry players incldues new product launches and collaborations. For instance, in April 2016, the novel TransCarotid Artery Revascularization (TCAR) procedure launched by Silk Road Medical, Inc, received FDA approval. This minimally invasive technique is designed to access the common carotid artery. Moreover, in March, 2015, WATCHMAN, a closure device designed to prevent stroke in patients with atrial fibrillation received FDA approval.

Browse Sample of the Report @ https://www.marketresearchfuture.com/sample_request/5423

Rising cases of ischemia stroke are driving the demand for surgical procedures in stroke treatment. Increasing demand for minimally invasive procedures and advancements in surgical procedures are the key factors boosting the growth of the global ischemic stroke market. High cost of the surgical procedures and excessive usage of medication for the treatment of ischemic stroke are hindering the market growth.

The global market for ischemic stroke is expected to grow at a CAGR of approximately 8.3% during the forecast period 2017-2023.

Intended Audience:

• Ischemic Stroke Drug Suppliers
• Ischemic Stroke Drug Manufacturers
• Research and Development (R&D) Companies
• Medical Research Laboratories
• Academic Medical Institutes and Universities

Segmentation:

The ischemic stroke is segmented on the basis of diagnosis, drug class, surgery and end-users.

On the basis of the diagnosis, the market is segmented into Computed Tomography (CT), Magnetic resonance imaging (MRI), carotid ultrasound, cerebral angiography, electrocardiography, echocardiography, and others.

On the basis of the drug class, the market is segmented into tissue plasminogen activator, anticoagulant, antiplatelet, antihypertensive, and others

On the basis of the surgery, the market is segmented into carotid endarterectomy, angioplasty, and endovascular mechanical thrombectomy

On the basis of the end-user, the market is segmented into hospitals & clinics, medical institutes, research organization, and others.

Regional Analysis:                     

The global ischemic stroke market consists of countries namely America, Europe, Asia Pacific, and the Middle East and Africa.

The Americas has emerged as the largest market for the global ischemic stroke owing to the favorable government initiatives, technological innovations, and increasing demand for ischemic stroke products. According to the American Heart Association, ischemic stroke is among the top three causes of death in the U.S. and Canada, nearly 795,000 patients suffering from strokes are treated in the 2014.

Europe is the second largest global ischemic stroke market owing to the advancements in the surgical devices technology along with the rising occurrence of acute ischemia stroke cases among the patients. In the European Union, over 31 million people are living with diabetes aged between 20 and 79. This signifies an average diabetes prevalence rate of 8.6% of the adult population. Some other factors driving the market includes the growing percentage of diabetes mellitus population mainly in the developed countries of Europe

Asia Pacific is anticipated to unfold as the most promising market for the global ischemic stroke owing to increasing prevalence of stroke cases in this region. China and India are considered as a big market for ischemic stroke within the forecast period. Manufacturers are expanding their operations in Asia Pacific region as these regions hold immense potential for the market growth.

The Middle East region is expected to grow at a faster rate due to the factors such as the extensive development of healthcare infrastructure and growing emphasis on research and development in the healthcare sector.

Key Players:

The emergence of new and cost-effective medication options for the treatment of ischemic stroke could open up new opportunities to the new players in the global ischemic stroke market. Additionally, emerging markets, such as India and China, could also open new opportunities to new players.

Some of key the players in the Americas ischemic stroke market are Abbott Laboratories (U.S.), Medtronic plc (U.S.), Boston Scientific Corporation (U.S.), Cordis Corporation (U.S.),  Koninklijke Philips N.V. (Netherland), GE Healthcare (U.S.), Stryker Corporation (U.S.), Genentech, Inc. (U.S.), Merck & Co., Inc. (U.S.),  Bayer AG (Germany), Boehringer Ingelheim (Germany), Sanofi (France), Covidien plc (Ireland), Philips Healthcare (U.S.), Johnson & Johnson (U.S.), Penumbra, Inc. (U.S.),  GE Healthcare (U.S.),  Siemens Healthcare (U.S.), Hitachi, Ltd (Japan), Biogen (U.S.), Daiichi Sankyo (U.S.), Pfizer Inc. (U.S.), and others

Browse More Details of the Report @ https://www.marketresearchfuture.com/reports/ischemic-stroke-market-5423